Filing Flows › Beta Bionics (BBNX) › Q2 2026
Beta Bionics (BBNX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 29, 2026
Beta Bionics (BBNX) reported revenue of $32.0M for the second quarter 2026 (Q2 2026), +38% from a year earlier and +16% from the quarter before. Operating margin was -79.9%, net loss $23.4M (73.1% of revenue).
Beta Bionics, Q2 2026: revenue $32.0M (+38% year over year), operating margin -79.9%, net loss $23.4M, operating cash flow −$14.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.0M | +16% | +38% |
| Operating profit | −$25.6M | — | — |
| Net earnings | −$23.4M | — | — |
| Operating cash flow | −$14.6M | — | — |
What changed
Revenue was $32.0M in Q2 2026, up 38% year over year and up 16% from the previous quarter.
Gross margin was 59.0%, up 5.2 points from Q2 2025. Operating costs exceeded revenue by $25.6M, an operating margin of -79.9%. Operating expenses grew 37% against revenue growth of 38%. The fastest-growing cost line was Sales & marketing (+58%). The quarter ended with a net loss of $23.4M, wider than the previous quarter's $21.9M loss.
Operating cash flow was −$14.6M. Non-cash charges added back $709K of depreciation and $7.0M of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$15.7M.
Questions
What was Beta Bionics' revenue in the second quarter 2026?
Beta Bionics (BBNX) reported revenue of $32.0M for the second quarter 2026 (Q2 2026), +38% from a year earlier and +16% from the quarter before.
Was Beta Bionics profitable in the second quarter 2026?
Operating loss was $25.6M (-79.9% of revenue) and net loss $23.4M.
Source: Beta Bionics 10-Q on SEC EDGAR.